JP2025503502A - 化合物及びｈｄａｃ６阻害剤としてのその使用 - Google Patents
化合物及びｈｄａｃ６阻害剤としてのその使用 Download PDFInfo
- Publication number
- JP2025503502A JP2025503502A JP2024538291A JP2024538291A JP2025503502A JP 2025503502 A JP2025503502 A JP 2025503502A JP 2024538291 A JP2024538291 A JP 2024538291A JP 2024538291 A JP2024538291 A JP 2024538291A JP 2025503502 A JP2025503502 A JP 2025503502A
- Authority
- JP
- Japan
- Prior art keywords
- alkylene
- alkyl
- heterocycloalkyl
- compound
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21217182.1 | 2021-12-22 | ||
| EP21217181.3 | 2021-12-22 | ||
| EP21217181 | 2021-12-22 | ||
| EP21217182 | 2021-12-22 | ||
| PCT/EP2022/087613 WO2023118507A2 (en) | 2021-12-22 | 2022-12-22 | Compounds and use thereof as hdac6 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025503502A true JP2025503502A (ja) | 2025-02-04 |
| JP2025503502A5 JP2025503502A5 (https=) | 2026-01-07 |
| JPWO2023118507A5 JPWO2023118507A5 (https=) | 2026-01-07 |
Family
ID=84981649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024538291A Pending JP2025503502A (ja) | 2021-12-22 | 2022-12-22 | 化合物及びｈｄａｃ６阻害剤としてのその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20250051319A1 (https=) |
| EP (1) | EP4452265A2 (https=) |
| JP (1) | JP2025503502A (https=) |
| KR (1) | KR20240124952A (https=) |
| AU (1) | AU2022420827A1 (https=) |
| CA (1) | CA3239992A1 (https=) |
| IL (1) | IL313636A (https=) |
| MX (1) | MX2024007904A (https=) |
| WO (1) | WO2023118507A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| AU2020321955A1 (en) | 2019-07-30 | 2022-03-17 | Eikonizo Therapapeutics, Inc. | HDAC6 inhibitors and uses thereof |
| MX2024007904A (es) * | 2021-12-22 | 2024-09-18 | Augustine Therapeutics | Compuestos y uso de estos como inhibidores de hdac6. |
| IL316201A (en) | 2022-04-08 | 2024-12-01 | Eikonizo Therapeutics Inc | Oxadiazole HDAC6 inhibitors and their uses |
| WO2024261327A1 (en) * | 2023-06-21 | 2024-12-26 | Augustine Therapeutics | 2-(heteroaryl-thio)-1-(heteroaryl)ethanone compounds and use thereof as hdac6 inhibitors |
| KR20260025099A (ko) * | 2023-06-21 | 2026-02-23 | 어거스틴 테라퓨틱스 | 헤테로아릴-아민 화합물 및 이의 hdac6 억제제로서의 용도 |
| WO2024261328A1 (en) * | 2023-06-21 | 2024-12-26 | Augustine Therapeutics | Amide-amine compounds and use thereof as hdac6 inhibitors |
| WO2026027696A1 (en) * | 2024-07-31 | 2026-02-05 | Augustine Therapeutics | Thiomethyl carbonyl compounds and use thereof as hdac6 inhibitors |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| WO2005014588A1 (en) | 2003-08-01 | 2005-02-17 | Argenta Discovery Limited | Substituted thienyl-hydroxamic acids having histone deacetylase activity |
| US20090023798A1 (en) | 2007-06-15 | 2009-01-22 | Pharmacyclics, Inc. | Thiohydroxamates as inhibitors of histone deacetylase |
| JP5640005B2 (ja) | 2008-07-14 | 2014-12-10 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｄａｃおよび／またはｃｄｋ阻害剤としてのイミダゾシルピリジン化合物 |
| GB0813403D0 (en) | 2008-07-22 | 2008-08-27 | Lectus Therapeutics Ltd | Potassium ion channel modulators & uses thereof |
| US8546588B2 (en) | 2010-02-26 | 2013-10-01 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| CA2800717A1 (en) * | 2010-05-27 | 2011-12-01 | Bayer Intellectual Property Gmbh | Heterocyclic thiosubstituted alkanol derivatives as fungicides |
| US20130227717A1 (en) | 2010-10-08 | 2013-08-29 | Life Sciences Research Partners Vzw | Hdac inhibitors to treat charcot-marie-tooth disease |
| JP6338601B2 (ja) | 2013-03-01 | 2018-06-06 | フンダシオン パラ ラ インベスティガシオン メディカ アプリカダ | ホスホジエステラーゼとヒストンデアセチラーゼの二重阻害剤としての新規な化合物 |
| WO2017053360A1 (en) | 2015-09-22 | 2017-03-30 | The Board Of Trustees Of The University Of Illinois | Bicyclic and tricyclic cap bearing mercaptoacetamide derivatives as histone deacetylase inhibitors |
| US11584733B2 (en) * | 2017-01-09 | 2023-02-21 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
| US12310967B2 (en) | 2017-12-21 | 2025-05-27 | Gliapharm Sa | Compositions and methods of treatment for neurological disorders comprising motor neuron diseases |
| ES2749743B2 (es) | 2018-09-21 | 2020-12-14 | Consejo Superior Investigacion | Derivados de purina inhibidores de cdc7 y su uso para el tratamiento de patologias neurologicas |
| WO2021133957A1 (en) * | 2019-12-27 | 2021-07-01 | Onkure, Inc. | Benzimidazole compounds as hdac6 inhibitors |
| EP4111863A1 (en) | 2021-07-02 | 2023-01-04 | EuroChem Antwerpen | Phosphorus use efficiency enhancers as plant growth promotors |
| MX2024007904A (es) * | 2021-12-22 | 2024-09-18 | Augustine Therapeutics | Compuestos y uso de estos como inhibidores de hdac6. |
| US20240139187A1 (en) | 2022-10-12 | 2024-05-02 | The Children's Medical Center Corporation | Selective hypothalamus permeable hdac6 inhibitors for treatment of leptin-resistant obesity |
-
2022
- 2022-12-22 MX MX2024007904A patent/MX2024007904A/es unknown
- 2022-12-22 KR KR1020247023082A patent/KR20240124952A/ko active Pending
- 2022-12-22 EP EP22844102.8A patent/EP4452265A2/en active Pending
- 2022-12-22 AU AU2022420827A patent/AU2022420827A1/en active Pending
- 2022-12-22 US US18/723,237 patent/US20250051319A1/en active Pending
- 2022-12-22 WO PCT/EP2022/087613 patent/WO2023118507A2/en not_active Ceased
- 2022-12-22 CA CA3239992A patent/CA3239992A1/en active Pending
- 2022-12-22 IL IL313636A patent/IL313636A/en unknown
- 2022-12-22 JP JP2024538291A patent/JP2025503502A/ja active Pending
-
2025
- 2025-01-10 US US19/016,827 patent/US12421222B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20250051319A1 (en) | 2025-02-13 |
| IL313636A (en) | 2024-08-01 |
| US12421222B2 (en) | 2025-09-23 |
| WO2023118507A2 (en) | 2023-06-29 |
| KR20240124952A (ko) | 2024-08-19 |
| EP4452265A2 (en) | 2024-10-30 |
| AU2022420827A1 (en) | 2024-06-13 |
| US20250145604A1 (en) | 2025-05-08 |
| WO2023118507A3 (en) | 2023-08-03 |
| MX2024007904A (es) | 2024-09-18 |
| CA3239992A1 (en) | 2023-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025503502A (ja) | 化合物及びｈｄａｃ６阻害剤としてのその使用 | |
| CN116635371B (zh) | 一种作为sos1抑制剂的多环哒嗪酮类衍生物、其制备方法及用途 | |
| CN115806550B (zh) | 双环bet布罗莫结构域抑制剂及其用途 | |
| JP6663021B2 (ja) | 窒素含有縮合複素環化合物、製造方法、中間体、組成物および使用 | |
| KR20190112000A (ko) | Rho-키나아제 억제제로서 티로신 아마이드 유도체 | |
| CN112055710A (zh) | 作为lpa拮抗剂的环己基酸吡唑吖嗪 | |
| CN119654315A (zh) | 作为qpctl和qpct抑制剂用于治疗癌症的3-(6-吡啶-3-基)-2-[4-(4-甲基-4h-1,2,4-三唑-3-基)哌啶-1-基]苯甲腈衍生物和类似化合物 | |
| EP4308244A1 (en) | Heterocyclic derivatives as janus kinase inhibitors | |
| TWI891227B (zh) | 用於治療與apj受體活性相關的病狀的化合物及組成物 | |
| CN111433196A (zh) | 新颖缓激肽b2受体拮抗剂及其用途 | |
| AU2018286247A1 (en) | Syk inhibitor and use method therefor | |
| AU2021303635A1 (en) | Heterocyclic immunomodulator | |
| TWI783480B (zh) | 用於抑制cdk7之化合物 | |
| CN112279837B (zh) | 吡嗪化合物和其用途 | |
| CN111747954B (zh) | 吡嗪化合物和其用途 | |
| CN114650988A (zh) | 作为二氢乳清酸脱氢酶(dhodh)抑制剂用于治疗癌症、自身免疫性和炎性疾病的氟化喹啉和喹喔啉衍生物 | |
| CN115427109A (zh) | 作为二氢乳清酸脱氢酶抑制剂的杂环化合物 | |
| CN118591375A (zh) | 作为hdac6抑制剂的化合物及其用途 | |
| CN117209501A (zh) | 磺酰胺衍生物及其用途 | |
| KR20260025099A (ko) | 헤테로아릴-아민 화합물 및 이의 hdac6 억제제로서의 용도 | |
| WO2024261327A1 (en) | 2-(heteroaryl-thio)-1-(heteroaryl)ethanone compounds and use thereof as hdac6 inhibitors | |
| WO2024261328A1 (en) | Amide-amine compounds and use thereof as hdac6 inhibitors | |
| EA052513B1 (ru) | Соединения и их применение в качестве ингибиторов hdac6 | |
| TWI920043B (zh) | Gem二取代之雜環化合物及其作為idh抑制劑之用途 | |
| TWI910148B (zh) | 芳基或雜芳基衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251219 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251219 |